ELOX

Eloxx Pharmaceuticals Inc

Jun 12 • 04:00PM ET

13.52

+0.88 6.96 %

Healthcare • Biotechnology • USA • Nano • NASD

Jun 10, 10:01 AMDilutive $66M public offering and Nasdaq uplisting trigger ELOX 24% drop

Index	-	P/E	-	EPS (ttm)	-	Insider Own	29.60%	Shs Outstand	0.46M	Perf Week	118.06%
Market Cap	0.57M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.03M	Perf Month	58428.14%
Enterprise Value	-5.80M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	27.81%	Perf Quarter	1228990.92%
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.70	Perf Half Y	1228990.92%
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.01M	Perf YTD	1228990.96%
Book/sh	-16.44	P/C	0.09	EPS next 5Y	-	ROE	-	52W High	13.25 2.04%	Perf Year	1228990.92%
Cash/sh	151.09	P/FCF	-	EPS past 3/5Y	75.85% 61.60%	ROIC	-	52W Low	- -	Perf 3Y	-78.70%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	29.75% 121.05%	Perf 5Y	-98.38%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	2.49	Perf 10Y	-99.33%
Dividend Ex-Date	-	Quick Ratio	0.48	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	69.74	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.48	EPS Q/Q	97.33%	SMA20	152.20%	Beta	-147692.01	Target Price	330.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	359.05%	Rel Volume	4.30	Prev Close	12.64
Employees	10	LT Debt/Eq	-	Earnings	-	SMA200	618.13%	Avg Volume	11.88K	Price	13.52
IPO	Dec 11, 1998	Option/Short	No / Yes	EPS/Sales Surpr.	40.89% -	Trades		Volume	51,030	Change	6.96%

Eloxx Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of novel ribonucleic acid-modulating drug candidates. It focuses on the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Arlington, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ELOX

Eloxx Pharmaceuticals Inc

Upgrade your Finviz experience